The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Open accessPublished version of a preprint
Abstract
SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. Here, we systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in unexposed individuals, exposed family members, and individuals with acute or convalescent COVID-19. Acute-phase SARS-CoV-2-specific T cells displayed a highly activated cytotoxic phenotype that correlated with various clinical markers of disease severity, whereas convalescent-phase SARS-CoV-2-specific T cells were polyfunctional and displayed a stem-like memory phenotype. Importantly, SARS-CoV-2-specific T cells were detectable in antibody-seronegative exposed family members and convalescent individuals with a history of asymptomatic and mild COVID-19. Our collective dataset shows that SARS-CoV-2 elicits broadly directed and functionally replete memory T cell responses, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [113]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [113]
The cited source says what the claim attributes to it.
In the citing paper
“A vast majority of responding CD4+ and CD8+ T cells displayed an activated/cycling (CD38+ HLA-DR+ Ki67+ PD-1+) phenotype [113]”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [113]
The cited source says what the claim attributes to it.
In the citing paper
“and SARS-CoV-2-specific memory T cells were detected in convalescent patients, even in exposed individuals who are seronegative.30, 31”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [31]
In the citing paper
“Virus-specific CD8+ and CD4+ T cells, including CD8+ memory T cells, are present in patients who have recovered from COVID-19 (refs44,45), but their importance in protection against future infection and/or severe disease remain uncertain44,46–48.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [45]
In the citing paper
“By contrast, VAERD has not usually occurred if a TH1 cell-biased CD4+ T cell response is elicited, reflected by increased levels of interferon-γ (IFNγ), IL-2 and tumour necrosis factor (TNF)44–46,49.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [45]
In the citing paper
“Studies of acute and convalescent COVID-19 patients have observed that SARS-CoV-2-specific T cell responses are significantly associated with milder disease (Liao et al., 2020; Rydyznski Moderbacher et al., 2020; Sekine et al., 2020; Zhou et al., 2020b), suggesting that T cell responses may be important for control and resolution of a primary SARS-CoV-2 infection.”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Sekine et al., 2020
In the citing paper
“Overall, circulating SARS-CoV-2-specific CD8+ T cells are less consistently observed than CD4+ T cells (Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Sekine et al., 2020
In the citing paper
“Last, there were initially great concerns about potential immune deviation to Th2 and immunopathogenesis (Peeples, 2020), but SARS-CoV-2-specific CD4+ T cells from patients consistently do not have Th2 characteristics (Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Sekine et al., 2020
In the citing paper
“CD4+ T cell responses to SARS-CoV-2 are more prominent than CD8+ T cell responses (Grifoni et al., 2020; Sekine et al., 2020) and have been associated with control of primary SARS-CoV-2 infection (Rydyznski Moderbacher et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Sekine et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationThe third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,002
Netti, G. S., Infante, B., Troise, D. E., Mercuri, S., Panico, M., Spadaccino, F., Catalano, V., Gigante, M., Simone, S., Pontrelli, P., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.16958 · Cited by 64
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67
Liu, R., Zhao, L. Y., Cheng, X., Han, H. W., Li, C., Dong, L., Liu, A., Gao, G., Zhou, F., Liu, F., et al. (2020) · Liver International · doi:10.1111/liv.14774 · Cited by 64
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
Nakano, Y., Kurano, M., Morita, Y., Shimura, T., Yokoyama, R., Qian, C., Xia, F., He, F., Kishi, Y., Okada, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82428-5 · Cited by 64
Harrington, P., Doores, K. J., Radia, D. H., O’Reilly, A., Lam, H. P. J., Seow, J., Graham, C., Lechmere, T., McLornan, D. P., Dillon, R. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17568 · Cited by 62
Havervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 63
Self-citationImmune responses in mildly versus critically ill COVID-19 patients
Nasrollahi, H., Talepoor, A. G., Saleh, Z., Vakili, M. E., Heydarinezhad, P., Karami, N., Noroozi, M., Meri, S., & Kalantar, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1077236 · Cited by 63
Mazzoni, A., Maggi, L., Capone, M., Spinicci, M., Salvati, L., Colao, M. G., Vanni, A., Kiros, S. T., Mencarini, J., Zammarchi, L., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048915 · Cited by 61
Karim, F., Gazy, I., Cele, S., Zungu, Y., Krause, R., Bernstein, M. P., Khan, K., Ganga, Y., Rodel, H. E., Mthabela, N., et al. (2021) · eLife · doi:10.7554/elife.67397 · Cited by 64
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Mazzotti, L., Gaimari, A., Bravaccini, S., Maltoni, R., Cerchione, C., Juan, M., González‐Navarro, E. A., Pasetto, A., Silva, D. N., Ancarani, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158590 · Cited by 64
Host Recovery from Respiratory Viral Infection
Wei, X., Narasimhan, H., Zhu, B., & Sun, J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-040450 · Cited by 63
Wells, P. M., Doores, K. J., Couvreur, S., Martínez-Nuñez, R. T., Seow, J., Graham, C., Acors, S., Kouphou, N., Neil, S. J. D., Tedder, R. S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.10.011 · Cited by 60
Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity
Lee, E., Sandgren, K. J., Duette, G., Stylianou, V. V., Khanna, R., Eden, J., Blyth, E., Gottlieb, D. J., Cunningham, A. L., & Palmer, S. (2020) · Journal of Virology · doi:10.1128/jvi.02002-20 · Cited by 62
Manisty, C., Treibel, T. A., Jensen, M. P., Semper, A. E., Joy, G., Gupta, R. K., Cutiño‐Moguel, T., Andiapen, M., Jones, J., Taylor, S. C., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103259 · Cited by 60
SARS-CoV-2-specific immune response in COVID-19 convalescent individuals
Pan, Y., Jiang, X., Yang, L., Chen, L., Zeng, X., Liu, G., Tang, Y., Qian, C., Wang, X., Cheng, F., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00686-1 · Cited by 61
Shahbaz, S., Xu, L., Sligl, W., Osman, M. S., Bozorgmehr, N., Mashhouri, S., Redmond, D., Rosero, E. P., Walker, J. W. T., & Elahi, S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100446 · Cited by 63
Infection fatality rate of COVID-19 in community-dwelling elderly populations
Axfors, C., & Ioannidis, J. P. A. (2022) · European Journal of Epidemiology · doi:10.1007/s10654-022-00853-w · Cited by 62
SARS-CoV-2 and mitochondrial health: implications of lifestyle and ageing
Nunn, A. V. W., Guy, G. W., Brysch, W., Botchway, S. W., Frasch, W. D., Calabrese, E. J., & Bell, J. D. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00204-x · Cited by 60
Almendro-Vázquez, P., Laguna‐Goya, R., Ruiz‐Ruigómez, M., Utrero‐Rico, A., Lalueza, A., de la Calle, G. M., Delgado, P., Ordoño, L. P., Muro, E., Vila, J. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010211 · Cited by 60
Vikkurthi, R., Ansari, A., Pai, A. R., Jha, S. N., Sachan, S., Pandit, S., Nikam, B., Kalia, A., Jit, B. P., Parray, H. A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01161-5 · Cited by 61
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Yilmaz, I. C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Guvencli, N., Aydin, Y., Gungor, B., et al. (2021) · Allergy · doi:10.1111/all.15091 · Cited by 63
Principles and Challenges in anti-COVID-19 Vaccine Development
Strizova, Z. O., Smetanová, J., Bartůňková, J., & Milota, T. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514225 · Cited by 58
Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help
Pušnik, J., Richter, E., Schulte, B., Dolscheid‐Pommerich, R., Bode, C., Putensen, C., Hartmann, G., Alter, G., & Streeck, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109320 · Cited by 59
Agrati, C., Castilletti, C., Goletti, D., Meschi, S., Sacchi, A., Matusali, G., Bordoni, V., Petrone, L., Lapa, D., Notari, S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9061315 · Cited by 58
Rénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 62
Askenase, P. W. (2020) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12004 · Cited by 58
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
Sui, Y., Bekele, Y., & Berzofsky, J. A. (2021) · Pathogens · doi:10.3390/pathogens10020138 · Cited by 57
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
Petrone, L., Petruccioli, E., Alonzi, T., Vanini, V., Cuzzi, G., Fard, S. N., Castilletti, C., Palmieri, F., Gualano, G., Vittozzi, P., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.02.023 · Cited by 58
Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients
Youngs, J., Provine, N. M., Lim, N. T. Y., Sharpe, H., Amini, A., Chen, Y., Luo, J. F., Edmans, M. D., Zacharopoulou, P., Chen, W., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009804 · Cited by 57
Castelli, E. C., de Castro, M. V., Naslavsky, M. S., Scliar, M. O., Silva, N. D. S. B., Andrade, H. S., Souza, A. S., Pereira, R. N., Castro, C. F. B., Mendes‐Junior, C. T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742881 · Cited by 59
Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency
Arroyo‐Sánchez, D., Cabrera-Marante, Ó., Laguna‐Goya, R., Almendro-Vázquez, P., Carretero, O., Gil‐Etayo, F. J., Suàrez-Fernández, P., Pérez‐Romero, P., de Frías, E. R., Serrano, A., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01174-5 · Cited by 57
Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients
Hurme, A., Jalkanen, P., Heroum, J., Liedes, O., Vara, S., Melin, M. M., Teräsjärvi, J. T., He, Q., Pöysti, S., Hänninen, A. L. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869990 · Cited by 60
Brasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S. A., Intinis, C. D., Fesi, F., Gizzi, K., Macagno, M., Montone, M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01313-z · Cited by 58
Vick, S. C., Frutoso, M., Mair, F., Konecny, A., Greene, E., Wolf, C. R., Logue, J. K., Franko, N., Boonyaratanakornkit, J. B., Gottardo, R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj0274 · Cited by 58
Kang, C. K., Kim, M., Lee, S., Kim, G., Choe, P. G., Park, W. B., Kim, N. J., Lee, C., Kim, I. S., Jung, K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab159 · Cited by 56
Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses
Siggins, M. K., Thwaites, R. S., & Openshaw, P. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.016 · Cited by 61
Shrwani, K. J., Sharma, R. S., Krishnan, M., Jones, T., Neto, M. M., Cantoni, D. M., Temperton, N. J., Dobson, S. L., Subramaniam, K. S., McNamara, P. S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab333 · Cited by 58
Pham, M. N., Murugesan, K., Banaei, N., Pinsky, B. A., Tang, M. C., Hoyte, E. G., Lewis, D. B., & Gernez, Y. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.11.022 · Cited by 56
A chitosan-mediated inhalable nanovaccine against SARS-CoV-2
Zhuo, S., Wu, J., Zhao, L., Li, W., Zhao, Y., & Li, Y. (2022) · Nano Research · doi:10.1007/s12274-021-4012-9 · Cited by 56
Pathogenesis‐directed therapy of 2019 novel coronavirus disease
Stratton, C. W., Tang, Y., & Lu, H. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26610 · Cited by 59
Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão
da Sílva, A. A. M., Neto, L. G. L., de Azevedo, C. D. M. P. E. S., da Costa, L. M. M., Bragança, M. L. B. M., Filho, A. K. D. B., Wittlin, B. B., de Souza, B. F., de Oliveira, B. L. C. A., de Carvalho, C. A., et al. (2020) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2020054003278 · Cited by 57
Ferreras, C., Pascual-Miguel, B., Mestre‐Durán, C., Navarro‐Zapata, A., Villa, L. C., Martín-Cortázar, C., de Paz, R., Marcos, A., Vicario, J., Balas, A., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.620730 · Cited by 55
Funk, C. D., Laferrière, C. A., & Ardakani, A. (2021) · Viruses · doi:10.3390/v13030418 · Cited by 57
Favà, A., Donadeu, L., Sabé, N., Pernin, V., González‐Costello, J., Lladó, L., Meneghini, M., Charmetant, X., García‐Romero, E., Cachero, A., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16570 · Cited by 59
Stanczak, M. A., Sanin, D. E., Apostolova, P., Nerz, G., Lampaki, D., Hofmann, M., Steinmann, D., Krohn-Grimberghe, M., Thimme, R., Mittler, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22449-w · Cited by 57
Mysore, V., Culleré, X., Settles, M. L., Ji, X., Kattan, M. W., Desjardins, M., Durbin-Johnson, B. P., Gilboa, T., Baden, L. R., Walt, D. R., et al. (2021) · Med · doi:10.1016/j.medj.2021.08.004 · Cited by 56
Chiuppesi, F., Zaia, J. A., Frankel, P. H., Stan, R., Drake, J., Williams, B., Acosta, A. M., Francis, K., Taplitz, R. A., Dickter, J. K., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00027-1 · Cited by 55
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
Mouro, V., & Fischer, A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00517-8 · Cited by 56
Airway-resident T cells from unexposed individuals cross-recognize SARS-CoV-2
Diniz, M. O., Mitsi, E., Swadling, L., Rylance, J., Johnson, M., Goldblatt, D., Ferreira, D. M., & Maini, M. K. (2022) · Nature Immunology · doi:10.1038/s41590-022-01292-1 · Cited by 55
Brüssow, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15302 · Cited by 54
Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2
Yu, K. K. Q., Fischinger, S., Smith, M. T., Atyeo, C. G., Cizmeci, D., Wolf, C. R., Layton, E. D., Logue, J. K., Aguilar, M. S., Shuey, K. D., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146242 · Cited by 56
Nelson, R. W., Chen, Y., Venezia, O. L., Majerus, R. M., Shin, D. S., MGH COVID-19 Collection & Processing Team, Carrington, M. N., Yu, X. G., Wesemann, D. R., Moon, J. J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl9464 · Cited by 56
Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors
Tarke, A., Potestà, M., Varchetta, S., Fenoglio, D., Iannetta, M., Sarmati, L., Mele, D., Dentone, C., Bassetti, M., Montesano, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137155 · Cited by 55
COVID‐19 immunopathology: From acute diseases to chronic sequelae
Arish, M., Qian, W. G., Narasimhan, H., & Sun, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28122 · Cited by 55
Role of T cells in severe COVID-19 disease, protection, and long term immunity
Hermens, J. M., & Keşmir, C. (2023) · Immunogenetics · doi:10.1007/s00251-023-01294-9 · Cited by 57
Brown, B., Ojha, V., Fricke, I., Al-Sheboul, S. A., Imarogbe, C., Gravier, T., Green, M., Peterson, L., Koutsaroff, I. P., Demir, A. N., et al. (2023) · Vaccines · doi:10.3390/vaccines11020408 · Cited by 55
Correlates of Vaccine-Induced Protection against SARS-CoV-2
Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M., & Dahlke, C. (2021) · Vaccines · doi:10.3390/vaccines9030238 · Cited by 57
A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)
Mohammed, R. N., Tamjidifar, R., Rahman, H. S., Adili, A., Ghoreishizadeh, S., Saeedi, H., Thangavelu, L. P., Shomali, N., Aslaminabad, R., Marofi, F., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00856-w · Cited by 53
Resolving SARS-CoV-2 CD4+ T cell specificity via reverse epitope discovery
Pogorelyy, M. V., Rosati, E., Minervina, A. A., Mettelman, R. C., Scheffold, A., Franke, A., Bächer, P., & Thomas, P. G. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100697 · Cited by 56
Delivery Routes for COVID-19 Vaccines
Park, J. H., & Lee, H. K. (2021) · Vaccines · doi:10.3390/vaccines9050524 · Cited by 53
Cellular immune responses to covid-19
Sewell, H. F., Agius, R. M., Stewart, M., & Kendrick, D. (2020) · BMJ · doi:10.1136/bmj.m3018 · Cited by 53
Zenarruzabeitia, O., Astarloa-Pando, G., Terrén, I., Orrantia, A., Pérez-Garay, R., Seijas, I., Arana, J. N., Imaz-Ayo, N., Pérez-Fernández, S., Arana‐Arri, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655934 · Cited by 54
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells
Hafezi, B., Chan, L., Knapp, J. P., Karimi, N., Alizadeh, K., Mehrani, Y., Bridle, B. W., & Karimi, K. (2021) · Cells · doi:10.3390/cells10071761 · Cited by 52
Rank, A., Tzortzini, A., Kling, E., Schmid, C., Claus, R., Loell, E., Burger, R., Römmele, C., Dhillon, C., Müller, K., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153305 · Cited by 53
Zonozi, R., Walters, L. C., Shulkin, A., Naranbhai, V., Nithagon, P., Sauvage, G., Kaeske, C., Cosgrove, K. M., Nathan, A., Tano-Menka, R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4529 · Cited by 52
Thymic Aging May Be Associated with COVID-19 Pathophysiology in the Elderly
Wang, W., Thomas, R. G., Oh, J., & Su, D. (2021) · Cells · doi:10.3390/cells10030628 · Cited by 52
Tan, C. C. S., Owen, C. J., Tham, C. Y. L., Bertoletti, A., van Dorp, L., & Balloux, F. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105075 · Cited by 54
Gastrointestinal Involvement in SARS-CoV-2 Infection
Chen, T., Hsu, M., Lee, M., & Chou, C. (2022) · Viruses · doi:10.3390/v14061188 · Cited by 56
Andrade, V. M., Christensen-Quick, A., Agnes, J. T., Tur, J., Reed, C., Kalia, R., Marrero, I., Elwood, D., Schultheis, K., Purwar, M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00384-7 · Cited by 51
Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?
Söderberg‐Nauclér, C. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00218-z · Cited by 51
Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19
Neurath, M. F., Überla, K., & Ng, S. C. (2021) · Gut · doi:10.1136/gutjnl-2021-324622 · Cited by 50
Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers
Jeewandara, C., Kamaladasa, A., Pushpakumara, P. D., Jayathilaka, D., Aberathna, I. S., Danasekara, D. R. S. R., Guruge, D., Ranasinghe, T., Dayarathna, S., Pathmanathan, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24579-7 · Cited by 50
Brazeau, N. F., Verity, R., Jenks, S. J., Fu, H. J., Whittaker, C., Winskill, P., Dorigatti, I., Walker, P. G. T., Riley, S., Schnekenberg, R. P., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00106-7 · Cited by 50
Stevens, J., Steinmeyer, S. H., Bonfield, M., Peterson, L. S., Wang, T. C., Gray, J. K., Lewkowich, I. P., Xu, Y. J., Du, Y., Guo, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl3981 · Cited by 50
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50
Kim, D. S., Rowland‐Jones, S., & Gea‐Mallorquí, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.571481 · Cited by 51
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages
Motamedi, H., Ari, M. M., Dashtbin, S., Fathollahi, M., Hossainpour, H., Alvandi, A., Moradi, J., & Abiri, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107763 · Cited by 51
A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
Steinbuck, M. P., Seenappa, L. M., Jakubowski, A., McNeil, L. K., Haqq, C. M., & DeMuth, P. C. (2021) · Science Advances · doi:10.1126/sciadv.abe5819 · Cited by 49
Current and prospective computational approaches and challenges for developing COVID-19 vaccines
Hwang, W., Lei, W., Katritsis, N. M., MacMahon, M., Chapman, K. L., & Han, N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.004 · Cited by 51
SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review
Grant, R., Dub, T., Andrianou, X. D., Nohynek, H., Wilder‐Smith, A., Pezzotti, P., & Fontanet, A. L. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045425 · Cited by 49
Ameratunga, R., Longhurst, H. J., Steele, R. H., Lehnert, K., Leung, E. Y., Brooks, A. E. S., & Woon, S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.019 · Cited by 49
Xu, K., Dai, L., & Gao, G. F. (2021) · International Immunology · doi:10.1093/intimm/dxab061 · Cited by 48
Bruno, P. M., Timms, R. T., Abdelfattah, N. S., Leng, Y., Lelis, F., Wesemann, D. R., Yu, X. G., & Elledge, S. J. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01566-x · Cited by 50
Dalai, S. C., Dines, J. N., Snyder, T. M., Gittelman, R., Newman-Eerkes, T., Vaney, P., Howard, S., Akers, K., Skewis, L. R., Monteforte, A. J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac353 · Cited by 49
mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
Rauch, S., Gooch, K., Hall, Y., Salguero, F. J., Dennis, M. J., Gleeson, F. V., Harris, D., Ho, C., Humphries, H. E., Longet, S., et al. (2020) · doi:10.1101/2020.12.23.424138 · Cited by 48
Echeverría, G. A., Guevara, A. G., Coloma, J., Ruiz, A. M., Vasquez, M. M., Tejera, E., & de Waard, J. H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.034 · Cited by 49
Hu, C., Shen, M., Han, X., Chen, Q., Luo, L., Chen, S., Zhang, J., Gao, F., Wang, W., Wang, Y., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.05.006 · Cited by 47
COVID-19: systemic pathology and its implications for therapy
Shen, Q., Li, J., Zhang, Z., Guo, S., Wang, Q., An, X., & Chang, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.65911 · Cited by 51
Impaired Humoral Immunity Is Associated With Prolonged COVID-19 Despite Robust CD8 T-Cell Responses
Lyudovyk, O., Kim, J. Y., Qualls, D. A., Hwee, M. A., Lin, Y.-H., Boutemine, S. R., Elhanati, Y., Solovyov, A., Douglas, M., Chen, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.013 · Cited by 48
SARS-CoV-2–specific B- and T-cell immunity in a population-based study of young Swedish adults
Björkander, S., Du, L., Zuo, F., Ekström, S., Wang, Y., Wan, H., Sherina, N., Schoutens, L., Andréll, J., Andersson, N., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.10.014 · Cited by 49
Self-citationLafon, E., Diem, G., Witting, C., Zaderer, V., Bellmann-Weiler, R. M., Reindl, M., Bauer, A., Griesmacher, A., Fux, V., Hoermann, G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684014 · Cited by 46
Liu, G., Carter, B., & Gifford, D. K. (2020) · Cell Systems · doi:10.1016/j.cels.2020.11.010 · Cited by 48
Palmer, S., Cunniffe, N. J., & Donnelly, R. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2020.0982 · Cited by 47
Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics
Nagler, A., Kalaora, S., Barbolin, C., Gangaev, A., Ketelaars, S. L. C., Alon, M., Pai, J. A., Benedek, G., Yahalom-Ronen, Y., Noam Erez, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109305 · Cited by 47
Heide, J., Schulte, S., Kohsar, M., Brehm, T. T., Herrmann, M., Karsten, H., Marget, M., Peine, S., Johansson, A. M., Sette, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009842 · Cited by 46
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 48
Elyanow, R., Snyder, T. M., Dalai, S. C., Gittelman, R. M., Boonyaratanakornkit, J. B., Wald, A., Selke, S., Wener, M. H., Morishima, C., Greninger, A. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.150070 · Cited by 46
Seo, Y. B., Suh, Y. S., Ryu, J. I., Jang, H., Oh, H., Koo, B., Seo, S. H., Hong, J. J., Song, M., Kim, S.-J., et al. (2021) · Vaccines · doi:10.3390/vaccines9040307 · Cited by 48
SARS-CoV-2 Antibody Dynamics and B-Cell Memory Response Over-Time in COVID-19 Convalescent Subjects
Achiron, A., Gurevich, M., Falb, R., Dreyer-Alster, S., Sonis, P., & Mandel, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.008 · Cited by 45
Metadata
- Authors
- Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., Wullimann, D. J., Kammann, T., Emgård, J., Parrot, T., Folkesson, E., Akber, M., Berglin, L., Bergsten, H., Brighenti, S., Brownlie, D., Butrym, M., Chambers, B., Chen, P., Jeannin, M. C., Grip, J., Gomez, A. C., Dillner, L., Lozano, I. D., Dzidic, M., Tullberg, M. F., Färnert, A., Glans, H., Haroun-Izquierdo, A., Henriksson, E., Hertwig, L., Kalsum, S., Kokkinou, E., Kvedaraite, E., Loreti, M., Lourda, M., Maleki, K., Malmberg, K.-J., Marquardt, N., Maucourant, C., Michaelsson, J., Mjösberg, J., Moll, K., Muva, J., Mårtensson, J., Nauclér, P., Norrby-Teglund, A., Medina, L. P., Persson, B., Radler, L., Ringqvist, E., Sandberg, J. T., Sohlberg, E., Soini, T., Svensson, M., Tynell, J., Varnaite, R., Kries, A. V., Unge, C., Rooyackers, O., Eriksson, L. I., Henter, J.-I., Sönnerborg, A., Allander, T., Albert, J., Nielsen, M., Klingström, J., Gredmark-Russ, S., Björkström, N. K., Sandberg, J. K., Price, D. A., Ljunggren, H.-G., Aleman, S., & Buggert, M.
- Affiliations
- Karolinska Institutet (SE)
- Karolinska University Hospital (SE)
- National University of General San Martín (AR)
- University Hospital of Wales (GB)
- Corresponding author
- Buggert, Marcus
- ORCID
- Sekine, Takuya
- Strålin, Kristoffer
- Gorin, Jean-Baptiste
- Kamal, Habiba
- Wullimann, David J.
- Kammann, Tobias
- Parrot, Tiphaine
- Folkesson, Elin
- Bergsten, Helena
- Brighenti, Susanna
- Brownlie, Demi
- Butrym, Marta
- Chambers, Benedict
- Chen, Puran
- Grip, Jonathan
- Dillner, Lena
- Dzidic, Majda
- Färnert, Anna
- Glans, Hedvig
- Haroun-Izquierdo, Alvaro
- Hertwig, Laura
- Kalsum, Sadaf
- Kokkinou, Efthymia
- Kvedaraite, Egle
- Maleki, Kimia
- Malmberg, Karl-Johan
- Marquardt, Nicole
- Maucourant, Christopher
- Mjösberg, Jenny
- Mårtensson, Johan
- Nauclér, Pontus
- Ringqvist, Emma
- Sandberg, John Tyler
- Sohlberg, Ebba
- Soini, Tea
- Svensson, Mattias
- Tynell, Janne
- Rooyackers, Olav
- Henter, Jan-Inge
- Sönnerborg, Anders
- Albert, Jan
- Nielsen, Morten
- Klingström, Jonas
- Björkström, Niklas K.
- Sandberg, Johan K.
- Price, David A.
- Ljunggren, Hans-Gustaf
- Aleman, Soo
- Buggert, Marcus
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 183
- Issue
- 1
- Pages
- 158-168.e14
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC7427556
- OpenAlex
- W3048775784
- Cited by
- 1,788
- References
- 58
- Citations by year
- 2026: 50 · 2025: 97 · 2024: 150 · 2023: 221 · 2022: 424 · 2021: 624 · 2020: 220
- FWCI
- 48.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cell (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- RIUCAM (submittedVersion, cc-by-nc-nd)
- Funders
- Barncancerfonden
- Svenska Sällskapet för Medicinsk Forskning
- Jeanssons Stiftelser
- National Institutes of Health
- Vetenskapsrådet
- Karolinska Institutet
- Cancerfonden
- Åke Wiberg Stiftelse
- Magnus Bergvalls Stiftelse
- Stiftelsen Clas Groschinskys Minnesfond
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, T cell immunity, memory T cells, convalescent patients, asymptomatic infection, mild COVID-19, cytotoxic T lymphocytes, T cell polyfunctionality, family exposure, disease severity
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Antibodies, Viral, Convalescence, Female, Humans, Immunologic Memory, Male, Middle Aged, Pneumonia, Viral, T-Lymphocytes, Coronavirus Infections, Asymptomatic Infections, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
